Harbin Pharmaceutical Group Co Stock

Harbin Pharmaceutical Group Co ROE

The Return on Equity (ROE) of Harbin Pharmaceutical Group Co (600664.SS) as of Aug 23, 2026 is 11.75 %. In the previous year, Return on Equity (ROE) was 8.37 % — a change of 40.49% (higher).

ROE

11.75 %

YoY

40.49%

Last updated:

In 2026, Harbin Pharmaceutical Group Co's return on equity (ROE) was 11.75 %, a 40.49% increase from the 8.37 % ROE in the previous year.

The Harbin Pharmaceutical Group Co ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2017
5.77 CNY
Jan 1, 2018
5.90 CNY
Jan 1, 2019
1.03 CNY
Jan 1, 2020
-30.98 CNY
Jan 1, 2021
9.65 CNY
Jan 1, 2022
10.72 CNY
Jan 1, 2023
8.37 CNY
Jan 1, 2024
11.75 CNY
The Harbin Pharmaceutical Group Co ROE history
YEARROEYoY
11.75 %+40.49%
8.37 %-21.96%
10.72 %+11.16%
9.65 %-131.14%
-30.98 %-3,118.60%
1.03 %-82.60%
5.90 %+2.22%
5.77 %-42.49%
10.04 %+22.04%
8.22 %+174.27%
3.00 %—
Access this data via the Eulerpool API
Get Free API Key

Harbin Pharmaceutical Group Co Stock analysis

What does Harbin Pharmaceutical Group Co do? Harbin Pharmaceutical Group Co is one of the most popular companies on Eulerpool.

ROE Details

Decoding Harbin Pharmaceutical Group Co's Return on Equity (ROE)

Harbin Pharmaceutical Group Co's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Harbin Pharmaceutical Group Co's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Harbin Pharmaceutical Group Co's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Harbin Pharmaceutical Group Co’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Harbin Pharmaceutical Group Co stock

Return on Equity (ROE) of Harbin Pharmaceutical Group Co is 11.75 % in 2026.

Return on Equity (ROE) of Harbin Pharmaceutical Group Co changed from 8.37 % to 11.75 %, representing a 40.49% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Harbin Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Harbin Pharmaceutical Group Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API
Get Free API Key

Profitability — Harbin Pharmaceutical Group Co

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Harbin Pharmaceutical Group Co